RVMD Company Profile and Key Details

Q: Who are the executives of RVMD?

Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. David S. ArringtonSenior Vice President of Investor Relations & Corporation AffairsMr. David L. Pompliano Ph.D.Founding Chief Scientific OfficerDr. Mark A. Goldsmith Ph.D.Chief Executive Officer, Pres & ChairmanMr. Jack AndersChief Financial OfficerMs. Margaret A. Horn J.D.Chief Operating OfficerDr. Stephen M. Kelsey FRC Path., FRCP, M.D.Pres of R&DMs. Xiaolin WangExecutive Vice President of Clinical Devel.Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerDr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory Board

NASDAQ : RVMD

Revolution Medicines

$117.00

0.78+0.67%

Open: 3:53 PM

60.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Revolution Medicines, Inc. (RVMD) stock surged +0.67%, trading at $117.00 on NASDAQ, up from the previous close of $116.22. The stock opened at $115.60, fluctuating between $114.81 and $118.42 in the recent session.

Stock Snapshot

116.22

Prev. Close

22.62B

Market Cap

114.805

Day Low

-22.54

P/E Ratio

-5.19

EPS (TTM)

-2.54

Cash Flow per Share

115.6

Open

193.32M

Number of Shares

118.42

Day High

84.8%

Free Float in %

12.93

Book Value

2.63M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	118.59	119.75	113.96	116.22	5.16M
Jan 16, 2026	124.45	124.49	119.61	120.28	4.55M
Jan 15, 2026	120.70	124.16	120.70	123.27	2.95M
Jan 14, 2026	119.82	122.12	118.15	121.22	3.66M
Jan 13, 2026	118.16	121.30	117.78	119.95	3.61M
Jan 12, 2026	116.82	118.48	113.33	117.17	6.1M
Jan 09, 2026	120.00	121.62	109.77	118.64	20.72M
Jan 08, 2026	95.21	112.43	94.52	107.39	12.61M
Jan 07, 2026	80.95	105.00	79.94	102.71	14.04M
Jan 06, 2026	78.51	80.39	77.76	79.85	2.12M
Jan 05, 2026	78.44	78.94	76.28	78.33	3.09M
Jan 02, 2026	80.29	80.47	77.86	79.02	1.38M
Dec 31, 2025	79.68	80.30	79.46	79.65	830.34K
Dec 30, 2025	80.30	80.50	78.97	79.67	1.24M
Dec 29, 2025	80.01	80.93	79.81	80.52	1.69M
Dec 26, 2025	81.22	81.58	80.01	80.75	1.08M
Dec 24, 2025	80.51	81.97	80.01	81.19	1.4M
Dec 23, 2025	80.57	81.71	79.91	80.27	1.05M
Dec 22, 2025	78.40	81.62	78.40	80.58	1.7M
Dec 19, 2025	77.56	79.10	76.45	78.78	6.11M

Contact Details

Redwood City, CA 94063

United States

https://www.revmed.com 650 481 6801

About Company

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $117.00 USD, gaining $0.78 (0.67%) from the previous close of $116.22. The stock is currently mid-range between its 52-week high and low $29.17 and $124.49. With a market capitalization of about $22.62 billion, Revolution Medicines, Inc. is classified as a large-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 3.24 million shares, in line with its 52-week average. Headquartered in Redwood City, CA, Revolution Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark A. Goldsmith, the company employs approximately 616 people and listed since February 13, 2020. Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 20.72%, SMA50 41.1%, SMA200 125.67%). The stock’s 14-day RSI is 75.22 (overbought), while the ATR of 5.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.64% below its high and over 298.42% above its low. Average 10-day trading volume of 4.34 million shares is slightly above the 3-month average of 3.09 million, indicating heightened recent market interest.

Valuation Metrics

Revolution Medicines, Inc. trades at a P/E ratio of -22.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 13.71 reflecting a rich premium to book value. The P/FCF stands at -28.79, also below market averages. Compared to sector medians, Revolution Medicines, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Revolution Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.43. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Revolution Medicines, Inc. generated EPS of -$5.18 over the past year. Five-year average earnings growth is -27.8%. Wall Street analysts project EPS growth of -18.62% annually over the next five years. The latest quarter delivered EPS of -$1.61. The next quarter is forecast at -$1.58. Next year's EPS is expected at $4.13. Analyst sentiment is bullish. Analyst rating data shows there are 33 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $160.00 to $56.00. The high target offers 37.67% upside. The low target suggests -51.82% downside. The mean target is $77.90. This offers -32.97% upside. Revolution Medicines, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 15.83%. The prior quarter beat by 39.36%. Over the last six quarters, Apple has recorded several small beats. These include 5.19% in August 07, 2024.

Shareholding & Insider Activity

Revolution Medicines, Inc. has 186.93 million shares outstanding. The public float is 158.55 million shares, elevated short interest at 7.93% of float. This equals 13.93 million shares. The short ratio is 8.22 days. Institutional investors hold 106.47% of the float. Insiders own 2.01%. TEPPER ROBERT I holds 5.10 million shares, Schroeder Thilo has 760.87 thousand shares and Kelsey Stephen Michael has 278.60 thousand shares. Over the past six months, insider transactions show net selling. They sold 268.95 thousand shares across 26 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Revolution Medicines generated $11.58M in revenue, or $0.10 per share. Gross margin was 19.61%, operating margin -4207.12%, and net profit margin -3768.28%. Returns are negative, with ROA at -20.89% and ROE at -23.89%.
On valuation metrics, Revolution Medicines trades at a P/E of -22.79, P/S of 0.00 and P/B of 13.71. The current ratio is 8.05 and quick ratio is 8.05. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -4.81.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Revolution Medicines posted revenue of $11.58M, down slightly from $35.38M in the prior quarter. Gross profit was $2.27M (margin 19.61%). Operating income was - $487.19M (margin -4207.1%). Net income was- $436.37M (EPS - $3.86).
The company ended the quarter with $1.85B in cash and short-term investments, a total debt of $87.94M, and net debt of - $608.20M. Total assets were $2.09B, with equity of $1.83B. Financials further reflected weakness, with operating cash flow of - $350.57M, free cash flow of - $358.30M, and capital expenditures of - $7.73M.

Price Forecast & Outlook

Our AI price prediction model suggests that Revolution Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 26.02%, with price expected at $146.46 by February 03, 2026, within a range of $139.11 to $154.42 3-Month Outlook: Projected rise of 189.13%, reaching $336.03 by April 16, 2026, with a range of $333.84 to $343.89. 1-Year Outlook: Projected gain of 13.47%, with price at $131.87 by January 15, 2027, within a range of $128.40 to $135.45.

Key Takeaways

Revolution Medicines, Inc. (NASDAQ:RVMD) shares are up 45.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Revolution Medicines, Inc. trading at a premium to the broader market with a P/E of -22.79. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $65.07, suggesting -44.01% downside. Our AI forecast model points to short-term strength (26.02% over two weeks), a medium-term rise (189.13% over three months), and a longer-term gain (13.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Revolution Medicines, Inc. (RVMD) stock price?

Revolution Medicines, Inc. (NASDAQ: RVMD) stock price is $117.00 in the last trading session. During the trading session, RVMD stock reached the peak price of $118.42 while $114.81 was the lowest point it dropped to. The percentage change in RVMD stock occurred in the recent session was 0.67% while the dollar amount for the price change in RVMD stock was $0.78.

RVMD's industry and sector of operation?

The NASDAQ listed RVMD is part of Biotechnology industry that operates in the broader Healthcare sector. Revolution Medicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RVMD?

Dr. Michael A. Fischbach Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board
Mr. David S. Arrington
Senior Vice President of Investor Relations & Corporation Affairs
Mr. David L. Pompliano Ph.D.
Founding Chief Scientific Officer
Dr. Mark A. Goldsmith Ph.D.
Chief Executive Officer, Pres & Chairman
Mr. Jack Anders
Chief Financial Officer
Ms. Margaret A. Horn J.D.
Chief Operating Officer
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.
Pres of R&D
Ms. Xiaolin Wang
Executive Vice President of Clinical Devel.
Dr. Martin D. Burke M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Walter Reiher Ph.D.
Chief Information Officer
Dr. Kevan M. Shokat Ph.D.
Co-Founder and Member of Clinical & Scientific Advisory Board

How RVMD did perform over past 52-week?

RVMD's closing price is 298.42% higher than its 52-week low of $29.17 where as its distance from 52-week high of $124.49 is -6.64%.

How many employees does RVMD have?

Number of RVMD employees currently stands at 616.

Link for RVMD official website?

Official Website of RVMD is: https://www.revmed.com

How do I contact RVMD?

RVMD could be contacted at phone 650 481 6801 and can also be accessed through its website. RVMD operates from 700 Saginaw Drive, Redwood City, CA 94063, United States.

How many shares of RVMD are traded daily?

RVMD stock volume for the day was 2.63M shares. The average number of RVMD shares traded daily for last 3 months was 3.24M.

What is the market cap of RVMD currently?

The market value of RVMD currently stands at $22.62B with its latest stock price at $117.00 and 193.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	616
Beta	0.99
Sales or Revenue	$11.58M
5Y Sales Change%	-0.815%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RVMD Company Profile and Key Details

Revolution Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways

Earnings & Analyst Outlook